Abstract
Human noroviruses (NoVs) are highly contagious viral pathogens and the leading cause of virally induced gastroenteritis across all age groups.1 Currently, there are no approved therapeutics or vaccines available against NoVs. Adaptive immune control of NoVs in humans, especially humoral antibody responses, has been intensively analyzed in clinical settings, but T cell responses against NoVs have generally been understudied. NoV vaccine design has predominantly focused on antibody-mediated protection, targeting the structural portions of NoVs, but their success thus far has been limited.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Cellular and Molecular Gastroenterology and Hepatology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
